BIOCON vs GLENMARK: Stock Comparison
GLENMARK PHARMACEUTICALS is the larger company by market capitalisation. BIOCON shows a higher ROE, a higher dividend yield and a higher ROCE, while GLENMARK PHARMACEUTICALS shows a lower P/E, faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
BIOCON leads 5; GLENMARK leads 6 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | BIOCON | GLENMARK |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | BIOCON | GLENMARK |
|---|---|---|
| Live Price | ₹330.3 | ₹2,198.5 |
| Day Change | -1.4% | 0.2% |
| Volume | 21.36 L | 5.77 L |
| 52-Week High | ₹447.15 | ₹2,537.6 |
| 52-Week Low | ₹330.75 | ₹1,792.6 |
| Distance from 52W High | -26.13% | -13.36% |
Valuation
| Metric | BIOCON | GLENMARK |
|---|---|---|
| Market Cap | ₹53,739 Cr | ₹61,612 Cr |
| P/E Ratio | 98.43x | 41.17x |
| P/B Ratio | 1.57x | 5.86x |
| EPS | ₹0.87 | ₹17.11 |
| Book Value | ₹224.71 | ₹372.49 |
| Dividend Yield | 0.15% | 0.11% |
Growth
| Metric | BIOCON | GLENMARK |
|---|---|---|
| Revenue Growth (TTM YoY) | 2.3% | 14.3% |
| EPS Growth (TTM YoY) | -72.5% | 6,575% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | BIOCON | GLENMARK |
|---|---|---|
| ROE | 1.01% | -0.83% |
| ROCE | 2.35% | -0.79% |
| Net Margin | 2.29% | 8.15% |
| Operating Margin | 8.5% | -2.22% |
| Debt to Equity | 0.4x | 0x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | BIOCON | GLENMARK |
|---|---|---|
| Promoter Holding | 29.73%▼ 0.17 pp | 46.65% |
| FII Holding | 8.14%▲ 0.62 pp | 20.89%▲ 0.55 pp |
| DII Holding | 23.38%▼ 0.69 pp | 18.6%▼ 0.69 pp |
| Public Holding | 23.75%▲ 0.34 pp | 13.81%▲ 0.13 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: BIOCON and GLENMARK PHARMACEUTICALS.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.